Showing posts with label alzheimer's early diagnosis. Show all posts
Showing posts with label alzheimer's early diagnosis. Show all posts

Monday, October 15, 2012

The Latest Outlook On Alzheimer's Disease

Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

HuffingtonPost.com

By Keith Sinzinger, for U.S. News
More than 5 million Americans have Alzheimer's disease, and the nonprofit Alzheimer's Association projects that, barring major advances, 11 million to 16 million will have it by 2050--at an annual cost of $1.1 trillion in today's dollars. In May, the government announced the first national plan to combat Alzheimer's, and one focus is the role of beta-amyloid plaques in the brain, a leading suspect in this form of dementia. U.S. News spoke about progress against the disease with a leading researcher in the field, Reisa Sperling, head of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston and an associate professor of neurology at Harvard Medical School. Excerpts:
What do you see unfolding over the next couple of decades?
What we have now is what I would term "symptomatic therapy." Drugs that are FDA-approved for Alzheimer's disease help people stay functional a bit longer, but they're not really slowing the underlying disease process. I actually am optimistic about the outlook over the next 10 to 20 years, because I think we are realizing that Alzheimer's disease can be detected a decade before people have symptoms. That will allow us to move into the same type of prevention strategy that has been successful in cancer and heart disease.
Has anything proven effective yet in either staving off or slowing the disease?
Unfortunately, no. There are several anti-amyloid agents in large-scale trials that are due to report out this fall. However, those trials are being done at what we now recognize is probably the late stage of a 20-year disease process. And I'm afraid that may be too late for these particular mechanisms. The good news is that the agents are increasingly showing evidence that they have biologic activity, that they can lower amyloid in the brain and even affect what we call downstream processes, such as another key protein called tau. The issue is that we need to start both of those types of therapies, anti-amyloid and anti-tau, much earlier.
One of your specialties is early diagnosis. Are you seeing some important gains there?
We now have both imaging markers and biological markers in spinal fluid that can indicate the disease process very early, perhaps even before there are any symptoms. This is a huge advance. We screen for cholesterol and blood pressure before people have symptoms. We now have the ability to do that in Alzheimer's. The problem is we don't yet have large-scale studies to link these biomarkers to eventual clinical outcomes.
Given that there isn't any cure, might there be a downside in being able to make early diagnoses?
I don't believe that people who don't have symptoms yet should go out and get a PET scan or a spinal fluid test or even a genetic test, because it wouldn't change what I would recommend they do. I'd still recommend that they live a healthy lifestyle. What I'm working on is trying to do a prevention trial in people who have biomarker evidence of Alzheimer's disease but don't yet have any symptoms, and see if we could prevent the emergence of symptoms. That's what I think will be exciting over the next five years.
What are significant early warning signs of the disease?
For example, people worry they have Alzheimer's disease because they can't remember the actress's name in a film. That is not worrisome. But if they forget that they went to the movies at all, or forget what they were trying to remember, then I get worried. I also think that people losing interest in their hobbies and in social interaction is often a very concerning early sign. When people get lost driving even to familiar places, or get lost in an unfamiliar setting but can't figure out how to ask for help or reorient themselves, that's a real concern. One symptom that's very common is repeating questions multiple times.
Do you have advice for how people can best protect themselves, at any stage of life?
Physical exercise is showing more and more promise. I don't think there are definitive studies yet, but research does suggest that being in shape throughout life is helpful. And similarly, some exercise studies in patients who already have dementia show it seems to slow the rate of decline. There is some evidence that lower midlife cholesterol may be protective. And there's more and more evidence that early-life cognitively stimulating activities may be helpful. So one thing we can do is make sure we stay intellectually, socially, and physically active throughout our lives and help our kids start these habits early.

Monday, August 9, 2010

Early Detection for dementia- Is it worth the cost?

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Here are more interesting dementia brain boosting activities





Get your subscription to Activity Director Today's e magazine" />

EmpowHer

For the past 25 years, diagnosis of Alzheimer’s dementia has been based on clinical presentation. However, now experts from Alzheimer's Association and National Institutes on Aging have come up with newer guidelines to help make the diagnosis of this dreaded illness earlier.

William Thies, chief medical officer for the Alzheimer’s foundation, said, "These criteria will serve us in finding the kind of diagnostic tools and interventions that will help treat people in the earliest stages of the disease and avoid the severe symptoms that are so debilitating."

Since 1984, no new guidelines have been developed and the panel wanted to address the new advances in radiological imaging and use of biomarkers. At present, these experts do not currently recommend the use of biomarkers citing that many of the tests are not standardized and there is uncertainty how the markers relate to severity of the disease.

“We think that ultimately biomarker tests will help us be able to identify individuals with Alzheimer’s disease,” said Marilyn Albert, who chaired the panel’s workgroup on mild cognitive impairment. However, for now Albert said these markers are not ready to be used by physicians in clinical practice.

The experts hope to be able to assess individuals with “preclinical A.D.,” a term they coined to refer to individuals, chiefly those with a family history, who may have developed amyloidal matter in the brain but have not yet to develop symptoms of Alzheimer’s disease.

"Understanding the earlier stages may represent the best chance for treatment prior to symptoms becoming present," explained Dr. Reisa Sperling, of Brigham and Women's Hospital. “We want to be able to monitor a change from one's baseline over time."

While all this sounds magnificent, one should remember that these new diagnostic tools are simply more expensive scans, which are not yet approved by Medicare. With the current health budget crises, it is doubtful if Medicare will even pay for these scans. In many states, doctors have already been using these high-powered scans to determine presence of biomarkers to make diagnosis of Alzheimer’s dementia.

More importantly, there is a strong possibility that pharmaceutical companies could benefit from doctors who will start to prescribe more medications for early Alzheimer dementia, which in the first stages does not need any treatment.

Monday, September 22, 2008

Simple Blood Test Could Spot Alzheimer's Risk

Forbes
HealthDay News) -- A simple blood test to identify people at risk for Alzheimer's disease may be close at hand, according to researchers at Columbia University Medical Center in New York City.
They found that blood plasma levels of a peptide called Amyloid Beta (AB42) appear to increase before the onset of Alzheimer's and decrease shortly after a person develops the disease, which may be because AB42 becomes trapped in the brain.

"To date, AB42 levels have measured most reliably in the cerebrospinal fluid, which is more difficult to collect than blood. Blood draws can be done with relative ease and greater frequency than spinal taps, which is typically the way cerebrospinal fluid is collected," study lead author Nicole Schupf, associate professor of clinical epidemiology, said in a Columbia news release.

The study was published online Sept. 8 in the journal Proceedings of the National Academy of Sciences.

The finding is similar to that seen in heart attack patients, who...read the whole article
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info